SAN FRANCISCO, July 14 — The next generation of cancer immunotherapy is racing toward a milestone that could change how thousands of patients access treatment. Researchers are closing in on allogeneic CAR-T therapies — “off-the-shelf” cell therapies made from donor cells rather than a patient’s own — and the first such product could win FDA approval as early as next year. Here’s the problem with today’s approach.
Current CAR-T therapies are autologous, meaning they use a patient’s own immune cells. That requires a personalized manufacturing process that takes two to four weeks.
For someone with aggressive, relapsed cancer, that wait can feel like an eternity — and sometimes it’s time they simply don’t have. Allogeneic therapies aim to solve that. Think of it like moving from a bespoke tailor to a ready-to-wear shop.
Instead of custom-building a treatment for each individual patient, scientists take T-cells from a healthy donor, genetically edit them in bulk, and have them ready on the shelf for anyone who needs them. The practical upshot: faster access, potentially lower cost, and the ability to treat many more patients from a single manufacturing run.
The genetic engineering challenge
The hurdle has always been the immune system itself. If you infuse a stranger’s T-cells into a patient, those donor cells might attack the patient’s body — a dangerous condition called graft-versus-host disease. And the patient’s own immune system might reject the foreign cells before they can do their job.
Companies like Allogene Therapeutics and CRISPR Therapeutics are leading the charge to solve this. Their approach, demonstrated in a therapy called CTX-112 reported in June 2024, uses CRISPR-Cas9 gene-editing to knock out two specific targets: the endogenous T-cell receptor and a protein called CD52.
Knocking out the T-cell receptor prevents the donor cells from attacking the patient. Knocking out CD52 makes the cells resistant to lymphodepleting chemotherapy, which is typically used to clear space in the body before cell infusion. The result is a donor cell that can survive and work in multiple patients.
What the data shows
The early results are encouraging. A phase 1 trial of an allogeneic CAR-T product from Allogene Therapeutics, published in 2023, showed a 67% overall response rate in 40 patients with relapsed or refractory lymphoma. That’s a meaningful number for patients who have run out of standard options.
Another approach swaps out T-cells entirely. Fate Therapeutics is pioneering the use of natural killer, or NK, cells instead of T-cells.
A phase 1 trial in 2022 showed a 50% response rate in 30 patients. NK cells have a natural advantage: they’re less likely to cause graft-versus-host disease in the first place, which simplifies the genetic engineering required.
The bigger picture
The global pipeline is enormous. As of 2024, there were over 500 CAR-T clinical trials worldwide, with 50 of those in phase 3 — the final stage before seeking regulatory approval. That’s a staggering amount of activity for a field that essentially didn’t exist a decade ago.
If the first allogeneic CAR-T therapy receives FDA approval as early as 2025, it would mark a fundamental shift in how cell therapies are manufactured and delivered. Instead of a bespoke, patient-by-patient process that strains hospital supply chains, hospitals could one day order frozen vials of ready-to-use cells, thaw them, and infuse them the same day.
The practical upshot for patients: less waiting, more treating. And for a field that has already transformed outcomes for some blood cancers, that’s the next frontier worth watching.
